期刊文献+

冠心病患者通心络胶囊治疗后血栓调节蛋白、血管性血友病因子的变化观察 被引量:4

下载PDF
导出
摘要 目的探讨通心络胶囊对冠心病患者血管内皮功能的调节效果。方法以血栓调节蛋白(TM)、血管性血友病因子(vWF)作为评价血管内皮功能的指标,测定冠心病心绞痛患者应用通心络胶囊治疗前后血清TM、vWF含量。结果治疗前后,患者血清TM、vWF水平比较差异有统计学意义(P<0.05)。结论通心络胶囊可以改善冠心病患者的血管内皮功能。
出处 《国际检验医学杂志》 CAS 2011年第12期1350-1351,共2页 International Journal of Laboratory Medicine
  • 引文网络
  • 相关文献

参考文献11

二级参考文献50

  • 1郑萍,徐恩英.血栓调节蛋白、凝血酶-抗凝血酶复合物和D-二聚体在弥散性血管内凝血诊断中的应用[J].中国基层医药,2006,13(2):189-190. 被引量:6
  • 2王志新,李艳萍.弥漫性血管内凝血患者分子标志物的临床价值[J].医药论坛杂志,2006,27(6):94-95. 被引量:5
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5233
  • 4王鸿利 汪钟 等.血栓与止血实验室检查的应用.现代血栓病学[M].北京:北京医科大学中国协和医科大学联合出版社,1997.456-474.
  • 5Jones DW, Chambless LE, Folsom AR,et al. Risk factors for coronary heart disease in African[J]. Am Arch Intern Med, 2002,162:2565.
  • 6Inchiostro S, Dalfollo M, Marzano A,et al. Prevalence of diabetes and/or ischaernic heart disease in classes of increasing carotid altery atherosclerosis: An ultrasonographic study[J]. Diabetes Med, 2003,20: 670- 676.
  • 7Thomas GN, Chook P, Yip TW,et al, Smoking without exception adversely affects vascular structure and function in apparently healthy Chinese:Implications in global atherosclerosis prevention[J].Int J Cardiol, 2008,128(2) : 172-177.
  • 8Sever PS, Dahlof B. Pouher NR, et al. Prevention of coronary and stroke events with atorvastatinin hypertensive patients who have average or lower-than-aver-age cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm (ASCOTLLA): A multieentre randomised controlled Trial [J]. Lancet, 2003, 361:1149-1158.
  • 9Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events[J]. Ciculation,2000,102(13):1503-1510.
  • 10万楚成,夏云金,章正华,刘瑜,张霞,舒卫东.止凝血分子标志物在急性白血病合并DIC中的意义[J].临床内科杂志,2007,24(8):549-551. 被引量:5

共引文献108

同被引文献33

  • 1梁皓,赵文增.重要炎症因子与冠心病的关系[J].实用诊断与治疗杂志,2007,21(5):364-366. 被引量:27
  • 2叶福林,黄兵,杨银玉,等.高糖条件下外源性胰岛素对人脐静脉内皮细胞增殖凋亡及血管性血友病因子水平的影响[J].徐州医学院学报,2011;31(6):385-7.
  • 3McCarty O J, Conley RB, Shentu W, et al. Molecular imaging of activated von willebrand factor to detect high-risk atherosclerotic phenotype [ J ]. JACC : Cardiovascular Imaging, 2010 ; 3 ( 9 ) : 947-55.
  • 4陈灏珠.心脏病学(M].第5版.北京:人民卫生出版社,2000:227-9.
  • 5Cambronero F. Plasma levels of yon willebrand factor are increased in pa- tients with hypertrophic cardiomyopathy[ J]. Thromb Res, 2010 ;26 ( 1 ) : 46 -50.
  • 6温洪周,章翔,饶欢欢,等.CHD患者vWF和BNP的研究及临床意义[J].医药前沿,2012;2(3):393-4.
  • 7Cambronero F. Plasma levels of yon Willebrand factor are increased in patients with hypertrophic cardiomyopathy [ J ]. Thromb Res, 2010,26 ( 1 ) :46 -50.
  • 8Chao TH, Tsai WC, Chen JY, et al. Soluble thrombomodulin is a paracrine auti-apoptotic factor for vascular endothelial protection[ J]. int J Cardiol,2014,172 (2) :340 - 349.
  • 9Akbarzadeh Najar R, Ghaderian SM, Tabatabaei Panah AS. C-reactive protein (CRP) gene polymorphisms : implication in CRP plasma levels and susceptibility to acute myocardial infarction[J]. Mol Biol Rep,2012,39(4) :3 705 -3 712.
  • 10Bernard R, Corday E,Eliasch H,et al. Nomenclature and crite- ria for diagnosis of ischemic heart disease. Repod of the Joint International Society and Federation of Cardiology/world Health Organization task force on standardization of clinical nomenclature [ J ]. Circulation, 1979,59 (3) :607 - 609.

引证文献4

二级引证文献7

;
使用帮助 返回顶部